Related references
Note: Only part of the references are listed.The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline
Orit Bar-Am et al.
JOURNAL OF NEUROCHEMISTRY (2010)
Rasagiline: A novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity
Orly Weinreb et al.
PROGRESS IN NEUROBIOLOGY (2010)
Oxidative and Inflammatory Pathways in Parkinson's Disease
Rebecca L. Miller et al.
NEUROCHEMICAL RESEARCH (2009)
Comparative Neuroprotective Effects of Rasagiline and Aminoindan with Selegiline on Dexamethasone-Induced Brain Cell Apoptosis
Shawna Tazik et al.
NEUROTOXICITY RESEARCH (2009)
Glyceraldehyde-3-Phosphate Dehydrogenase-Monoamine Oxidase B-Mediated Cell Death-Induced by Ethanol is Prevented by Rasagiline and 1-R-Aminoindan
Xiao-Ming Ou et al.
NEUROTOXICITY RESEARCH (2009)
A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
C. Warren Olanow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
The neuroprotective effect of ladostigil against hydrogen peroxide-mediated cytotoxicity
Orly Weinreb et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2008)
Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration
Wen Zhu et al.
JOURNAL OF NEUROCHEMISTRY (2008)
Protective effects of salidroside on hydrogen peroxide-induced apoptosis in SH-SY5Y human neuroblastoma cells
Li Zhang et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2007)
Oxidative stress and dopamine depletion in an intrastriatal 6-hydroxydopamine model of Parkinson's disease
M. P. Smith et al.
NEUROSCIENCE (2007)
Protein aggregation in the pathogenesis of familial and sporadic Parkinson's disease
KSP McNaught et al.
NEUROBIOLOGY OF AGING (2006)
Binding of rasagiline-related inhibitors to human monoamine oxidases. a kinetic and crystallographic analysis
C Binda et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Effect of GABAA receptor stimulation in the subthalamic nucleus on motor deficits induced by nigrostriatal lesions in the rat
A Mehta et al.
EXPERIMENTAL NEUROLOGY (2005)
Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats
D Ben Shachar et al.
NEUROPHARMACOLOGY (2004)
Attenuation of methamphetamine induced dopaminergic neurotoxicity by flupirtine: microdialysis study on dopamine release and free radical generation
M Gassen et al.
JOURNAL OF NEURAL TRANSMISSION (2003)
Proteasomal inhibition-induced inclusion formation and death in cortical neurons require transcription and ubiquitination
HJ Rideout et al.
MOLECULAR AND CELLULAR NEUROSCIENCE (2002)
Proteasome inhibition causes nigral degeneration with inclusion bodies in rats
KS McNaught et al.
NEUROREPORT (2002)
Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells
S Abu-Raya et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2002)
Rat striatal monoamine oxidase-B inhibition by l-deprenyl and rasagiline: its relationship to 2-phenylethylamine-induced stereotypy and Parkinson's disease
MBH Youdim et al.
PARKINSONISM & RELATED DISORDERS (2002)
Proteasome inhibitors induce cytochrome c-caspase-3-like protease-mediated apoptosis in cultured cortical neurons
JH Qiu et al.
JOURNAL OF NEUROSCIENCE (2000)
Share Paper
